Skip to main content
Home

Language & Country Selector for Desktop

language-selector-globe United States | en

Choose Location

  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Latin America | es
  • Mexico | es
  • United States | en
  • Venezuela | es
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Taiwan | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Global | en
  • Novartis Foundation | en
  • Sandoz | en
  • Egypt | en
  • South Africa | en
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe United States

Choose Location

Americas Asia Pacific Europe International Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Global | en
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latin America | es
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Sandoz | en
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Venezuela | es
    • About 
      • Novartis in the US 
        • Company at a Glance 
        • By the Numbers 
        • Diversity and Inclusion 
        • Pay Transparency-EPIC 
        • Our Code of Ethics 
      • Strategy 
      • Diversity and Inclusion 
        • Ensuring Equity 
        • The Spirit of Inclusivity 
        • Toward a better society 
        • Parental Leave 
        • Standing for Racial Equity and Justice as One Novartis 
        • Novartis US EEO / D&I Report 2021 
        • Supplier Diversity 
      • People and Culture 
      • Products 
      • Country Leadership Team 
      • External Funding 
      • Contact Us 
      Woman scientist in lab About
    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Patient Assistance 
      • Diseases 
      • Participating in Clinical Trials 
      • Patient Perspectives 
      • Adverse Event Reporting 
      • The STEP Program 
        • Sickle Cell Disease (SCD) 
        • Program Overview 
        • Multiple Sclerosis (MS) 
        • Cancer 
        • Application for Funding to Help Address Health Disparities 
        • Health Disparities 
      Patient smiling at doctor image Patients and Caregivers
    • Healthcare Professionals 
      • Novartis Pipeline 
      • Novartis Clinical Trials 
      • Adverse Event Reporting 
      Two doctors examining X-ray Healthcare Professionals
    • ESG 
      • Ethical Behavior 
        • Code of Ethics 
        • SpeakUp 
        • PhRMA Code on Interactions with Healthcare Professionals 
        • Business Principles 
      • Ethics, Risk and Compliance 
        • Compliance Program 
        • State Laws 
        • Corporate Integrity Agreement 
        • Payments to HCPs & HCOs 
        • Enhanced Verification Request 
      • Corporate Responsibility 
        • Population Health 
        • Novartis in Society US Reports 
        • Novartis US Foundation 
        • Environmental Sustainability 
        • People and Communities 
      • Beacon of Hope 
        • Beacon of Hope: Measurable solutions for health equity 
      Novartis East Hanover Campus Landscaping ESG
    • News 
      • News Archive 
      • Statements 
      • Stories 
      • Contacts 
      Co-workers having a meeting News
    • Careers 
      • Career Search 
      • Meet the Teams 
      • Early Career 
      • Personal Growth 
      • How We Work 
      • Employee Benefits 
      • Diversity and Inclusion 
      • Awards & Recognition 
      Meeting in Atrium Careers
    • Coronavirus 
      coronavirus covid 19 hero image_0 Coronavirus
    Novartis East Hanover Campus East Village Promenade Home
  1. Home
  2. News
  3. News Archive
News Archive Navigation
  • All
  • Media Releases
  • Stories
  • Statements
icon
News Archive Navigation Language
  • English
  • French
  • German

December 2022

  • Media ReleaseDec 13, 2022
    Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5
    Trial met both primary and most secondary endpoints, showing iptacopan provided transfusion-free hemoglobin-level increases in vast majority of adult paroxysmal nocturnal hemoglobinuria (PNH)…
  • Media ReleaseDec 08, 2022
    Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH
    Phase III APPOINT-PNH study of investigational oral monotherapy iptacopan met its primary endpoint; second positive Phase III topline readout for iptacopan in paroxysmal nocturnal hemoglobinuria (PNH…
  • Media ReleaseDec 06, 2022
    Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
    RIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2− metastatic breast cancer (MBC), including visceral crisis, comparing a CDK4/6 inhibitor (CDK4/6i) plus…

November 2022

  • Media ReleaseNov 22, 2022
    Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH
    First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and…

July 2022

  • ripples in water 1600x800 stripe image_0
    StoryJul 11, 2022 Education and Awareness
    Our Collective Commitment to a DEI Movement

June 2022

  • Media ReleaseJun 30, 2022
    Novartis acquires Kedalion Therapeutics and its innovative ocular delivery platform that could transform patient experience
    Novartis acquires AcuStream™ platform, a novel topical ocular delivery device designed to facilitate dosing precision with the potential to support the delivery of front-of-eye therapies and help…
  • Media ReleaseJun 22, 2022
    Novartis expands Beacon of Hope through alliances with Historically Black Medical Schools to address systemic health disparities
    Novartis commits additional $17.7 million to create Clinical Trial Centers of Excellence at Howard University College of Medicine, Meharry Medical College and Charles R. Drew University of Medicine…
  • Media ReleaseJun 07, 2022
    Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
    Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-…

May 2022

  • Media ReleaseMay 28, 2022
    FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
    68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1Sustained clinical benefit from Kymriah…

April 2022

  • Media ReleaseApr 12, 2022
    Novartis presents new four-year data on efficacy and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
    Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension demonstrated the efficacy and safety of continuous Kesimpta® (ofatumumab) treatment and in those switched from teriflunomide, with…
  • Media ReleaseApr 06, 2022
    FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
    Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is characterized…

March 2022

  • Media ReleaseMar 24, 2022
    Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer
    FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2 Metastatic prostate cancer has a 5-year…

Pagination

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • › Next page

Novartis United States

Navigate Novartis
  • Patients & Caregivers
  • Healthcare Professionals
  • ESG
  • News
  • Careers
Media Center
  • News Archive
  • Statements
  • Stories
Our Portfolio
  • Novartis Clinical Pipeline
  • Novartis Product Portfolio
Other Novartis US Websites
  • Oncology HCP Resources
  • Gene Therapy Network
  • Medical Information
  • Sandoz
  • Global Site
Footer Bottom
© 2023 Novartis Pharmaceuticals Corporation
  • Terms of Use
  • Privacy Policy
  • Contacts
  • Site Map
  • Web Accessibility
Novartis Site Directory
This site is intended for US Residents Only